Sotakras 120 mg (Sotorasib) Tablets

Uses & Therapeutic Effects

Sotakras 120 mg contains sotorasib, a targeted anticancer medicine that inhibits the KRAS G12C protein. It is used in appropriately selected adults whose cancer has a confirmed KRAS G12C mutation.

Key therapeutic uses include:

• KRAS G12C-mutated non-small cell lung cancer (NSCLC): Sotorasib is used for adults with locally advanced or metastatic NSCLC who have received at least one previous systemic treatment.
• KRAS G12C-mutated metastatic colorectal cancer: Sotorasib may be used together with panitumumab in eligible adults whose disease has progressed after specified chemotherapy regimens.
• Targeted cancer therapy: The medicine specifically acts on the abnormal KRAS G12C signaling pathway rather than functioning as a conventional nonspecific cytotoxic chemotherapy.
• Disease-control treatment: By inhibiting mutant KRAS G12C signaling, sotorasib can interfere with cancer-cell growth and survival pathways.

Treatment eligibility depends on molecular testing confirming the KRAS G12C mutation and the patient's cancer history.

Important: Sotorasib is not a general treatment for every type of lung or colorectal cancer. Its use is linked to specific KRAS G12C-mutated cancers.

Active Ingredient

Sotorasib — 120 mg

Drug Class:
KRAS G12C inhibitor / Targeted anticancer therapy

Dosage Form:
Film-coated tablet

Composition Statement

Each Sotakras 120 mg tablet contains Sotorasib 120 mg as the active pharmaceutical ingredient.

The inactive ingredients/excipients can vary according to the specific manufacturer's formulation. Therefore, for your website, do not list excipients unless they are confirmed from the official product packaging, leaflet, or manufacturer documentation.

Recommended Dosage

The current FDA prescribing information recommends sotorasib 960 mg orally once daily for the approved NSCLC indication. For a 120 mg tablet strength, this corresponds to eight 120 mg tablets per day when the full 960 mg dose is prescribed.

How to Take Sotakras 120 mg

• Take the prescribed dose once daily.
• Sotorasib tablets may be taken with or without food.
• Swallow the tablets as directed by the treating physician.
• Do not change the dose or treatment schedule without medical supervision.
• Treatment generally continues until disease progression or unacceptable toxicity, according to the treating clinician's assessment.

If a Dose Is Missed

If a dose is missed and the next scheduled dose is more than 6 hours away, take the missed dose as soon as remembered. If the next dose is due within 6 hours, skip the missed dose and return to the regular schedule. Do not take two doses at the same time.

Important Administration Note

Because sotorasib can cause clinically important adverse reactions and drug interactions, the dose may need to be temporarily withheld, reduced, or discontinued by the treating physician. Liver function monitoring is particularly important during treatment.

For your product page, I recommend using this short dosage summary:

Sotakras 120 mg (Sotorasib) is an oral KRAS G12C inhibitor. The recommended sotorasib dose is 960 mg once daily, equivalent to eight 120 mg tablets when this strength is used. Take with or without food and follow the oncologist's prescribed treatment plan.